SecBot SecBot
PRESS-RELEASE ·Filed Jul 29, 2026

SNN

Smith & Nephew UK Ltd
BULLISH
Impact 6/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

The De Novo clearance creates a regulatory moat and positions SNN as the first entrant in AI-guided arthroscopic navigation. Monitor Q3 2026 commercial uptake and surgeon adoption metrics; competitor response from Stryker, J&J DePuy Synthes, and Arthrex will be key. The stock may see modest positive drift on this catalyst given the large-cap profile and modest immediate revenue impact.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$32.66
T+0 close · Jul 29, 2026 · via day close
Latest settled
−5.45%
T+60 · $30.88
Vs SPY
−10.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 29 $32.66entry
  2. T+1 · 4mo ago −1.01%α −2.69% · $32.33
  3. T+5 · 3mo ago −7.75%α −13.28% · $30.13
  4. T+20 · 3mo ago −10.29%α −15.31% · $29.30
  5. T+60 · 26d ago −5.45%α −10.18% · $30.88
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Smith+Nephew received FDA De Novo classification for its TESSA Spatial Surgery System, creating a new regulatory category for intra-articular orthopedic stereotaxic navigation instruments. The AI-powered augmented reality system is first indicated for ACL reconstruction surgery, addressing common tunnel placement errors. Commercial rollout begins Q3 2026.

Key Facts

  • FDA granted De Novo classification for TESSA Spatial Surgery System, establishing first device in new FDA category for intra-articular orthopedic stereotaxic navigation instruments
  • First indication is femoral anterior cruciate ligament reconstruction (ACLR) surgery, targeting femoral malposition (29%) and tibial malposition (11%) as common ACLR failure causes
  • System uses AI, NVIDIA accelerated computing, AWS cloud deep-learning neural nets, and augmented reality for patient-specific 3D anatomical models overlaid on live 4K arthroscopic video
  • Commercial introduction begins Q3 2026 with increased deployment expected in 2027
  • Smith+Nephew generated annual sales of $6.2 billion in 2025 with a market cap of $13.8 billion

Financial Impact

No specific revenue projections disclosed; De Novo classification opens a new product category in Sports Medicine, but for a $6.2B-revenue diversified medtech, near-term financial impact is moderate and will depend on early adoption rates in 2027

future revenue contribution from Sports Medicine segment

Risk Factors

  • Surgeon adoption may be slow given new technology learning curve and hospital capital budget constraints
  • Competitive AI/navigation systems from Stryker or other orthopedic players could follow quickly
  • Reimbursement pathway for the new device category is not yet established, potentially limiting volume in early years
  • Deployment ramp is back-end loaded to 2027, with limited 2026 revenue contribution

Market Snapshot

Exchange
OTC
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
50% bullish (24 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3335378

Track record

42 reports on SNN

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +8.02% at T+20 after the Jun 30, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 1/10 Entry $31.00 Now $30.97 −0.10% settles Nov 19
  2. Nov 4, 202612d ago 6-K Bearish 6/10 No price data
  3. Nov 4, 202612d ago 6-K Bearish 6/10 Entry $32.46 to $31.04 Now $30.97 +4.59% ▲ +4.37% +3.46% vs SPY
  4. Nov 2, 202614d ago 6-K Neutral 4/10 Entry $30.24 to $31.05 Now $30.97 +2.41% ▲ +2.68% +2.60% vs SPY
  5. Oct 22, 202625d ago 6-K Neutral 2/10 Entry $30.88 to $30.22 Now $30.97 +0.29% ▼ −2.14% −2.84% vs SPY
  6. Oct 8, 20265w ago 6-K Neutral 2/10 Entry $26.96 to $29.09 Now $30.97 +14.87% ▲ +7.90% +8.18% vs SPY
  7. Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
  8. Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
  9. Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
  10. Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
Showing 10 of 42

US Market Status

Market Closed · Opens Wed (10h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 29, 2026